INTRODUCTION {#S1}
============

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a common chronic inflammatory disease in the human upper airways and sinuses that affects approximately 0.5--4% of the general population in Europe, Asia and the US.^[@R1],\ [@R2]^ Immunologically, CRSwNP is characterized by type 2 inflammation with eosinophilia and high levels of type 2 cytokines including IL-5 and IL-13.^[@R1],\ [@R3]--[@R5]^ It has been reported that T~H~2 cells,^[@R6]^ mast cells^[@R7]^ and group 2 innate lymphoid cells (ILC2s),^[@R3],\ [@R8]--[@R10]^ which are able to produce type 2 cytokines, are accumulated in nasal polyps (NPs).^[@R9],\ [@R10]^ Among these cells, ILC2s are considered to be a key initiator and amplifier for type 2 inflammation due to the ability of these cells to produce type 2 cytokines via innate immune stimulation.^[@R10]^ We recently found that ILC2s were not only elevated but also activated and releasing type 2 cytokines in NPs.^[@R9]^ Thus far, the mechanisms controlling activation of ILC2s in NPs are still not understood. Epithelial cell-derived cytokines, IL-33, IL-25 and thymic stromal lymphopoietin (TSLP) are well known to control ILC2-mediated production of type 2 cytokines.^[@R3],\ [@R11]^ We recently characterized the presence of these epithelial-derived cytokines in NPs from CRSwNP patients in Chicago, Illinois and reviewed published studies for these cytokines in NPs.^[@R12]^ Interestingly, TSLP was certainly elevated in CRSwNP in most studies.^[@R12],\ [@R13]^ In contrast, IL-25 and IL-33 were not always elevated in NPs; there were mixed results in other parts of the world and thus, the relative importance of IL-25 and IL-33 in CRSwNP remains uncertain.^[@R12]^ Since TSLP alone does not induce the production of type 2 cytokines in ILC2s, and IL-25 and IL-33 are not elevated in NPs,^[@R8],\ [@R14]^ other factors, in addition to TSLP, may play important but unrecognized roles in ILC2-mediated type 2 inflammation in CRSwNP.

Recently, two separate groups have reported that death receptor 3 (DR3, TNF receptor superfamily 25 \[TNFRSF25\]) was expressed on human blood ILC2s and that a ligand TNF-like cytokine 1A (TL1A, TNF superfamily 15 \[TNFSF15\]) induced the production of IL-5 and IL-13 in human ILC2s.^[@R15],\ [@R16]^ They also found that TL1A synergistically enhanced IL-25- and IL-33-mediated production of IL-5 and IL-13 in human ILC2s.^[@R15]^ Furthermore, several groups also found that TNF receptor II (TNFRII \[TNFRSF1B\]) and glucocorticoid-induced TNFR related protein (GITR \[TNFRSF18\]) were expressed on ILC2s and their ligands, TNF and GITR-ligand induced type 2 cytokine production in ILC2s.^[@R10],\ [@R17],\ [@R18]^ Most members of the TNF receptor superfamily (TNFRSFs), including DR3, TNFRII and GITR, share a nuclear factor-kappa B (NF-κB) signal transduction pathway and play an important role in immunity and inflammation.^[@R10]^ However, the presence of TL1A, TNF, GITR-ligand and other TNF ligand superfamilies (TNFSFs) and their role in ILC2-mediated type 2 inflammation in NPs has not been well elucidated.

For this study, we hypothesized that members of TNFSF are closely involved in the ILC2-mediated type 2 inflammation in NPs and that the elevation of TSLP enhances the role of TNFSFs in CRSwNP. We therefore set out to define the presence of TNFSFs, their function in human ILC2s and their contribution to type 2 inflammation in CRSwNP.

RESULTS {#S2}
=======

The elevation of RANK-L in NPs {#S3}
------------------------------

To clarify the expression of TNFSFs in NPs, we analyzed our published microarray data in NPs compared to normal control uncinate tissue (UT)^[@R19]^ (GEO series GSE36830) and found that mRNAs for lymphotoxin beta (TNFSF3), receptor activator of NF-κB ligand (RANK-L, TNFSF11) and B cell activating factor of the TNF family (BAFF, TNFSF13B) were significantly elevated in NPs (not shown). Since we previously reported the elevation of BAFF in NPs,^[@R20]^ we performed qPCR for lymphotoxin beta and RANK-L and confirmed that they were both significantly elevated in NPs (n = 39) compared to control UT (n = 21) ([Fig. 1a](#F1){ref-type="fig"}, and not shown). We next examined the presence of receptors for these ligands on ILC2s by flow cytometry. The gating strategy used to identify ILC2s is shown in [Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}. We found that the receptor for RANK-L, RANK (receptor activator of NF-κB), but not the receptors for lymphotoxin beta or BAFF were expressed on both blood and NP ILC2s (n = 6) ([Fig. 1b](#F1){ref-type="fig"}, and not shown). Interestingly, cell surface expression of RANK was significantly higher on NP ILC2s than blood ILC2s ([Fig. 1b](#F1){ref-type="fig"}, [c](#F1){ref-type="fig"}). Based on the initial screen results and the presence of the receptor on human ILC2s, we decided to focus further studies on the RANK-L cascade in NPs. We next confirmed the presence of RANK-L protein in tissue homogenates and found that RANK-L protein was significantly elevated in NPs from patients with both non-steroidal anti-inflammatory drug (NSAID) tolerant (n = 69) and sensitive (n = 12) CRSwNP compared to control UT (n = 13) ([Fig. 1d](#F1){ref-type="fig"}). Since the endogenous decoy receptor of RANK-L, osteoprotegerin (OPG), may be present in NPs and it may affect RANK-L-mediated reactions, we also measured OPG mRNA by qPCR. Interestingly, we found that OPG was significantly reduced in NPs compared to control UT ([Fig. 1e](#F1){ref-type="fig"}, *left*). Consequently, the RANK-L/OPG ratio was significantly elevated in NPs compared to control UT ([Fig. 1e](#F1){ref-type="fig"}*, right*).

RANK-L induced production of type 2 cytokines in human ILC2s {#S4}
------------------------------------------------------------

Since we found elevation of ligand, RANK-L, in NPs and expression of receptor, RANK, on human ILC2s, we investigated the effect of the RANK-L to RANK cascade on human ILC2s sorted from blood and NP tissue. We found that an agonistic anti-RANK antibody but not goat control IgG significantly induced IL-5 and IL-13 on both blood and NP ILC2s ([Fig. 2a](#F2){ref-type="fig"}, [b](#F2){ref-type="fig"}, not shown). Although it was not potent as agonistic antibody, recombinant RANK-L also significantly induced the production of IL-13 in both blood and NP ILC2s ([Supplementary Fig. 2a](#SD1){ref-type="supplementary-material"}).

TSLP is known to act in synergy with IL-25 and IL-33,^[@R14],\ [@R21],\ [@R22]^ and is significantly elevated in NPs ([Supplementary Fig. 3a](#SD1){ref-type="supplementary-material"}).^[@R12],\ [@R13]^ We therefore examined whether RANK-L can act in synergy with TSLP on blood ILC2s. We found that TSLP significantly and synergistically enhanced RANK-L and anti-RANK antibody mediated production of type 2 cytokines in blood ILC2s ([Fig. 2c](#F2){ref-type="fig"}, and [Supplementary Fig. 2b](#SD1){ref-type="supplementary-material"}).

The binding of ligand, RANK-L, to receptor, RANK, mainly activates the NF-κB signaling pathway.^[@R23]^ We stimulated blood ILC2s with an agonistic anti-RANK antibody and TSLP, and examined the effect of glucocorticoid (dexamethasone, an inhibitor of the NF-κB pathway) and IMD0354, an inhibitor of IκB kinase-β1, on the production of IL-5 and IL-13. We found that dexamethasone and IMD0354 significantly suppressed RANK-mediated production of IL-5 and IL-13 in blood ILC2s ([Fig. 2d](#F2){ref-type="fig"}, [e](#F2){ref-type="fig"}). We previously reported that dexamethasone, IL-10 and transforming growth factor beta (TGF-β) inhibited IL-33-mediated production of type 2 cytokines in human ILC2s.^[@R22]^ We therefore investigated the inhibitory effects of IL-10 and TGF-β and found that IL-10 but not TGF-β1 significantly suppressed RANK-mediated production of type 2 cytokines in blood ILC2s ([Supplementary Fig. 2c](#SD1){ref-type="supplementary-material"}, [d](#SD1){ref-type="supplementary-material"}). These results suggest that NF-κB may be a key shared transcription factor controlling RANK-L− and IL-33-mediated induction of type 2 cytokines in human ILC2s.

The source of RANK-L in NPs {#S5}
---------------------------

RANK-L is a homotrimeric membrane bound protein that can be released from the cell surface by cleavage.^[@R24]^ Both the soluble and membrane bound forms of RANK-L are known to activate the receptor, RANK.^[@R24],\ [@R25]^ To examine the source of RANK-L in nasal mucosa, we used immunohistochemistry and flow cytometry. Immunohistochemical analysis showed that RANK-L was mainly detected on submucosal inflammatory cells and RANK-L positive cells were significantly elevated in NPs compared to control UT ([Fig. 3a](#F3){ref-type="fig"}--[e](#F3){ref-type="fig"}). Flow cytometric analysis showed that the frequency of RANK-L+ cells (median, range) in NPs was significantly higher in CD45+ cells (88.9%, 68.8--100%) compared to CD45− cells (11.1%, 0--31.3%) (n = 12) ([Fig. 3f](#F3){ref-type="fig"}). These results suggest that the main source of RANK-L in NPs is CD45+ immune cells and therefore we focused further studies on immune cells.

As RANK-L is known to be expressed on activated T cells, B cells and basophils in humans,^[@R26]--[@R29]^ we first determined the frequency of RANK-L+ cells in CD3+ T cells, CD19+ B cells, granulocytes (side scatter \[SSC\] high cells) and CD3-CD19− non-granulocytes (CD3-CD19^mid-low^ cells) ([Supplementary Fig. 4a](#SD1){ref-type="supplementary-material"}). We found that RANK-L was mainly detected on CD3-CD19− cells (median, range; 77.3%, 59.8%−96.1%) and CD3+ T cells (12.5%, 2.6%−24.8%) compared to CD19+ B cells (6.4%, 1.1--11.2%) and granulocytes (1.66%, 0--3.9%) within the population of CD45+ cells (n = 7) ([Fig. 4a](#F4){ref-type="fig"}). The % RANK-L+ cells in each cell type is shown in [Supplementary Fig. 4b](#SD1){ref-type="supplementary-material"}, [d](#SD1){ref-type="supplementary-material"}. We first focused on CD3+ T cells and found that RANK-L was highly expressed on CRTH2+CD4+ T~H~2 cells compared to CRTH2-CD4+ T cells and CD4− T cells in NPs ([Fig. 4d](#F4){ref-type="fig"}, [e](#F4){ref-type="fig"}, [Supplementary Fig. 5a](#SD1){ref-type="supplementary-material"}, and not shown). We further analyzed CD3-CD19− cells and found that RANK-L+ cells were mainly CD11c+ cells but not basophils (CD117-FcεRIa+), plasmacytoid dendritic cells (DCs) (BDCA4+), macrophages (CD68+), or mast cells (CD117+FcεRIa+) ([Fig 4b](#F4){ref-type="fig"}, [Supplementary Fig. 4c](#SD1){ref-type="supplementary-material"} and not shown). Bando et al. have reported expression of both RANK-L and RANK on mouse group 3 ILCs (ILC3s).^[@R30]^ We also investigated whether RANK-L is expressed on ILC subsets and found that RANK-L was weakly detected on ILC2s and CRTH2− ILCs which were a mixture of group 1 ILCs (ILC1s) and ILC3s (n = 5, [Supplementary Fig. 6a](#SD1){ref-type="supplementary-material"}). However, the expression of RANK-L on NP ILCs was similar to CRTH2-CD4+ T cells ([Supplementary Fig. 6b](#SD1){ref-type="supplementary-material"}). We therefore ruled out the importance of RANK-L in NP ILCs.

Since we found that a larger subset of RANK-L+CD11c+ cells expressed human leukocyte antigen-D related (HLA-DR) ([Supplementary Fig. 4d](#SD1){ref-type="supplementary-material"}), we initially hypothesized that RANK-L+CD11c+ cells were myeloid DCs (mDCs). However, the majority of these cells were not classical mDC1s (CD1c+) or mDC2s (CD141+) in NPs (n = 3) ([Fig. 4c](#F4){ref-type="fig"}, and [Supplementary Fig. 4e](#SD1){ref-type="supplementary-material"}). It has been reported that a subset of intestinal DCs express a membrane bound chemokine, CXCL16 on the cell surface and that these unique DCs interact with ILC3s via a CXCL16 receptor, CXCR6 dependent manner in mice.^[@R31]^ Interestingly, we found that the expression of RANK-L was significantly higher on CXCL16+HLA-DR+CD11c+ cells (called CXCL16+ cells) rather than on CXCL16-HLA-DR+CD11c+ cells ([Fig. 4f](#F4){ref-type="fig"}, [g](#F4){ref-type="fig"}, and [Supplementary Fig. 5b](#SD1){ref-type="supplementary-material"}). These results suggest that RANK-L is mainly expressed on T~H~2 cells and CXCL16+ antigen presenting cells in NPs.

Chemokines may play a role on the interaction of RANK-L expressing cells and ILC2s in NPs {#S6}
-----------------------------------------------------------------------------------------

We hypothesized that chemokines might play a role in the co-localization of ILC2s with RANK-L+CXCL16+ cells and T~H~2 cells in NPs. We first found that a CXCL16 receptor, CXCR6, was expressed on ILC2s in NPs ([Fig. 5a](#F5){ref-type="fig"}). This suggests that RANK-L+CXCL16+ cells may be able to interact with ILC2s in a CXCL16-CXCR6 dependent manner in NPs. We next found a high level of CCR4 on both T~H~2 cells and ILC2s in NPs ([Fig. 5b](#F5){ref-type="fig"}) which confirmed previous observations.^[@R21]^ We also found that mRNAs of the ligands for CCR4, CCL17 and CCL22 were significantly elevated in NP tissue compared to control UT ([Fig. 5c](#F5){ref-type="fig"}). These results suggest that the accumulation of CCR4 ligands may play a role in recruiting ILC2s and T~H~2 cells to the same area within NPs.

T~H~2 cells and CXCL16+ cells enhanced type 2 cytokine production in ILC2s {#S7}
--------------------------------------------------------------------------

Finally, we examined whether RANK-L+ cells are able to enhance ILC2-mediated production of type 2 cytokines. We performed a (1:1) co-culture using ILC2s with T~H~2 cells, CRTH2-CD4+ T cells or CXCL16+ cells sorted from NP tissue and compared production of type 2 cytokines from co-culture and individual culture ([Fig. 6a](#F6){ref-type="fig"}). We first found that NP ILC2s and T~H~2 cells (n = 12), but not CXCL16+ cells (n = 4) nor CRTH2-CD4+ T cells (n = 10) released type 2 cytokines without stimulation ([Supplementary Fig. 7](#SD1){ref-type="supplementary-material"}). We then found that the co-culture of ILC2s with T~H~2 cells significantly enhanced the production of IL-5 and IL-13 (5.0-fold and 4.2-fold, respectively, n = 12), compared to the sum of individual cultures ([Fig. 6c](#F6){ref-type="fig"}, [d](#F6){ref-type="fig"}). In contrast, the co-culture of ILC2s with CRTH2-CD4+ T cells did not enhance the production of type 2 cytokines ([Fig. 6b](#F6){ref-type="fig"}). Similarly, we found that the co-culture of ILC2s with CXCL16+ cells significantly enhanced the production of IL-5 and IL-13 (5.3-fold and 2.2-fold, respectively, n = 4, [Fig. 6e](#F6){ref-type="fig"}, [f](#F6){ref-type="fig"}). Finally, we found that a neutralizing anti-RANK-L antibody, denosumab, significantly suppressed the enhancement of type 2 cytokine production in the ILC2-Th2 cell co-culture ([Fig. 6g](#F6){ref-type="fig"}). These results suggest that T~H~2 cells and CXCL16+ cells enhance production of type 2 cytokines in ILC2s via a RANK-L mediated pathway and that interaction between ILC2s and RANK-L+ cells may play an important role in the amplification of type 2 inflammation in NPs.

DISCUSSION {#S8}
==========

RANK-L, RANK and RANK-L decoy receptor, OPG, play an essential role in osteogenesis, organization of lymphoid tissue and DC survival.^[@R24],\ [@R25]^ The dysregulation of RANK-L is involved in numerous diseases including osteoporosis, osteopetrosis, rheumatoid arthritis (RA), Paget's bone disease and periodontal disease.^[@R32]^ Denosumab, which is a fully human RANK-L monoclonal antibody, has been approved for treatment of diseases caused by overexpression of RANK-L.^[@R32]^ RANK-L was originally discovered as a co-stimulator in initiation of the acquired immune response, and RANK-L on activated T cells induces the survival signal or maturation of DCs via RANK.^[@R26],\ [@R33],\ [@R34]^ Herein, we report a novel role for RANK-L with findings suggesting that RANK-L is able to activate ILC2-mediated type 2 immunity.

We clearly showed that RANK-L and agonistic anti-RANK antibody induced production of type 2 cytokines in human ILC2s ([Fig. 2](#F2){ref-type="fig"} and [Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}) and that the levels of RANK-L in sinus tissue positively correlated with markers for type 2 inflammation including IL-13, eosinophil cationic protein (ECP), Charcot-Leyden crystal (CLC) and TSLP ([Supplementary Fig. 3b](#SD1){ref-type="supplementary-material"}, [c](#SD1){ref-type="supplementary-material"}). This suggests that RANK-L may be involved in controlling the type 2 inflammation in CRSwNP. However, the degree of cytokine production induced by RANK-L in ILC2s was not profound ([Fig. 2a](#F2){ref-type="fig"} and [Supplementary Fig. 2a](#SD1){ref-type="supplementary-material"}). It is well known that overexpression of RANK-L is associated with type 3 (T~H~17) inflammation but not with type 2 inflammation.^[@R35]^ This suggests that up-regulation of RANK-L alone may not be sufficient to induce type 2 inflammation. Importantly, we also found that TSLP potently enhanced RANK/RANK-L-mediated production of type 2 cytokines in human ILC2s ([Fig. 2c](#F2){ref-type="fig"} and [Supplementary Fig. 2b](#SD1){ref-type="supplementary-material"}). This suggests that RANK-L acts as an inducer and TSLP as an enhancer, that ILC2s are a target cell population to control initiation and amplification of type 2 immunity,^[@R10]^ and that the elevation of all three factors; inducer, enhancer and target cells, may be necessary to induce RANK-L-mediated type 2 inflammation. In the case of osteoporosis, RA and other type 3 inflammatory diseases, TSLP or ILC2s are probably not present nor elevated, and therefore overexpression of RANK-L may not induce type 2 inflammation in these diseases. In contrast, in CRSwNP, our studies indicate that the unique environment within NP tissue is characterized by accumulation of all three factors, RANK-L, TSLP and ILC2s, therefore enabling RANK-L to trigger type 2 inflammation, and explaining the positive correlation of RANK-L with type 2 inflammation in CRSwNP.^[@R9]^ It is well known that TSLP and ILC2s are highly elevated in many other type 2 inflammatory diseases, in addition to CRSwNP, including allergic asthma and atopic dermatitis.^[@R14],\ [@R21],\ [@R36]^ There may be value in future studies testing whether RANK-L is also elevated in other type 2 inflammatory diseases.

In an ancillary study, we found that RANK is also expressed on CRTH2− ILCs ([Supplementary Fig. 8a](#SD1){ref-type="supplementary-material"}, [b](#SD1){ref-type="supplementary-material"}). This suggests that over expression of RANK-L may influence ILC1 and/or ILC3-mediated inflammation in NPs. However, in view of the low frequency of ILC1/3 in CRSwNP compared to ILC2s,^[@R9]^ we think they may play only a minor role in NPs.

We found that the effect of agonistic anti-RANK antibody on the induction of type 2 cytokines in ILC2s was stronger than recombinant RANK-L protein ([Fig. 2](#F2){ref-type="fig"}, and [Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}). Both RANK-L and RANK have a homotrimeric structure and only trimeric RANK-L fully activates RANK on cells.^[@R37]--[@R39]^ However, recombinant RANK-L protein (amino acid: 64--245) may not form a complete trimeric structure because it is lacking several β-sheet structures, which are required to form the native trimeric RANK-L.^[@R39]^ In contrast, anti-RANK antibody can stimulate a homotrimeric RANK.^[@R39]^ This trimeric signaling may explain why anti-RANK antibody was more effective than recombinant RANK-L in activating ILC2s.

Although RANK is the only functional receptor for RANK-L, RANK-L decoy receptor, OPG, is secreted as a soluble form and competes with RANK-RANK-L binding.^[@R24],\ [@R25]^ It has been reported that soluble RANK-L complexed with OPG is a predominant form compared with free soluble RANK-L due to the high affinity interaction between RANK-L and OPG.^[@R40]^ In the present study, we found not only elevation of RANK-L but also down-regulation of OPG in NPs ([Fig. 1a](#F1){ref-type="fig"}, [e](#F1){ref-type="fig"}). This dual effect implies that OPG-free active RANK-L may be highly abundant in NPs compared to control nasal mucosa. We and others have previously reported that ILC2s are highly elevated in NPs.^[@R9],\ [@R10]^ We also found elevation of RANK expression on ILC2s in NPs ([Fig. 1b](#F1){ref-type="fig"}, [c](#F1){ref-type="fig"}). When combined with the finding that RANK-L is expressed on CXCL16+ DCs and that a CXCL16 receptor, CXCR6, is found on ILC2s these results suggest that within NP tissue there is a favorable environment for the interaction of OPG-free RANK-L on DCs and RANK on ILC2s; this interaction may well contribute to the initiation or perpetuation of type 2 inflammation in NPs. We also found that the co-culture of NP ILC2s with CXCL16+ cells enhanced ILC2-mediated production of type 2 cytokines ([Fig. 6e](#F6){ref-type="fig"}, [f](#F6){ref-type="fig"}). The results suggest that CXCL16+ cells may be involved in ILC2-mediated type 2 inflammation in CRSwNP at least in part via a RANK-L dependent manner. Since characterization of CXCL16+ cells in NPs is not well understood, advanced studies will be required to clarify the role of CXCL16+ cells in NPs.

We also demonstrated that RANK-L was highly expressed on T~H~2 cells in NPs ([Fig. 4d](#F4){ref-type="fig"}, [e](#F4){ref-type="fig"}). We then investigated how T~H~2 cells might co-localize with ILC2s and found that the chemokine receptor CCR4 was expressed on both T~H~2 cells and ILC2s in NPs, and that CCR4 ligands were elevated in NPs ([Fig. 5b](#F5){ref-type="fig"}, [c](#F5){ref-type="fig"}). Of further relevance to this question, others have found that PGD2 can recruit both T~H~2 cells and ILC2s via a CRTH2 dependent manner and that PGD2 is highly elevated in NPs, especially in patients who have NSAID sensitivity.^[@R41]--[@R44]^ These results suggest that CCR4 ligands and PGD2 may play important roles in both the accumulation and co-localization of ILC2s and T~H~2 cells to the same area within NPs. In the present study, we further analyzed a direct interaction between ILC2s and T~H~2 cells in NPs. We found that freshly isolated NP derived T~H~2 cells but not CRTH2-CD4+ T cells released type 2 cytokines without additional stimulation ([Supplementary Fig. 7](#SD1){ref-type="supplementary-material"}) and that NP T~H~2 cells were able to enhance the production of type 2 cytokines in NP ILC2s in a co-culture ([Fig. 6c](#F6){ref-type="fig"}, [d](#F6){ref-type="fig"}). These results suggest that T~H~2 cells not only actively release type 2 cytokines but also enhance ILC2-mediated type 2 inflammation in NPs *in vivo*. Recent studies suggest that T cells are able to directly interact with ILC2s through the ligation of OX40/OX40-ligand, inducible T-cell costimulatory (ICOS)/ICOS-ligand and programmed cell death 1 (PD-1)/PD-1 ligand 1.^[@R45]--[@R48]^ The role of these interactions on ILC2-mediated type 2 inflammation in NPs is still unclear. In support of the functional activation of a direct mechanism, we found that denosumab, almost completely abolished the enhanced active production of type 2 cytokines in a NP T~H~2-ILC2 co-culture ([Fig. 6g](#F6){ref-type="fig"}). Unexpectedly, we also found that RANK was expressed on T~H~2 cells ([Supplementary Fig. 8c](#SD1){ref-type="supplementary-material"}) and this observation indicates a potential RANK-RANK-L interaction within T~H~2 cells. However, we also found that agonistic anti-RANK antibody induced significantly less amounts of IL-5 and IL-13 in T~H~2 cells compared to ILC2s (4.2-fold and 89-fold, respectively, [Supplementary Fig. 8d](#SD1){ref-type="supplementary-material"}, [e](#SD1){ref-type="supplementary-material"}). In the terms of interaction, we were not able to detect soluble RANK-L in supernatants of NP T~H~2 cells (not shown). Taken together, these results suggests that the direct interaction of ILC2 and T~H~2 cell enhances type 2 cytokine responses and that the enhancement activity is mainly controlled by a RANK-L dependent activation of ILC2s. Clearly, future studies will be required to validate the mechanisms and quantify the importance of interaction between ILC2s and T~H~2 cells in controlling the production of type 2 cytokines in NPs.

In conclusion, we provide evidence that RANK-L, a member of the TNF superfamily, plays an inductive role in ILC2-mediated type 2 inflammation in NPs. TSLP clearly enhances the RANK-L-mediated production of type 2 cytokines from ILC2s in CRSwNP. Inhibition of the RANK-L/RANK axis and/or TSLP offers potentially effective strategies for suppression of ILC2-mediated type 2 inflammation in CRSwNP.

METHODS {#S9}
=======

Patients and tissue collection {#S10}
------------------------------

All control patients and patients with CRSwNP were recruited from the Otolaryngology clinic and the Northwestern Sinus Center of Northwestern Medicine. All CRS patients met the criteria for CRSwNP as defined by the International Consensus Statement on Allergy and Rhinology: Rhinosinusitis.^[@R49]^ Patients with an established immunodeficiency, pregnancy, coagulation disorder or diagnosis of eosinophilic granulomatosis with polyangiitis or cystic fibrosis were excluded from the study. Control patients were undergoing surgery for non-CRS indicated procedures such as septoplasty. All NP tissues were collected during endoscopic sinus surgery. Detailed characteristics of subjects in this study are shown in [Supplementary Table 1](#SD1){ref-type="supplementary-material"} and [2](#SD1){ref-type="supplementary-material"}. All subjects signed informed consent and the study was approved by the Institutional Review Board of Northwestern University Feinberg School of Medicine (IRB Project Number: STU00080917). Human peripheral blood leuko paks (STEMCELL Technologies, Vancouver, British Columbia, Canada) were obtained from healthy subjects for isolation of blood ILC2s and T cells.

Quantitative polymerase chain reaction (qPCR) {#S11}
---------------------------------------------

Total RNAs were isolated from whole tissue extracts and cDNA was prepared, as previously described.^[@R5],\ [@R12],\ [@R20]^ Real-time RT-qPCR was performed with the TaqMan method using a StepOnePlus Real-Time PCR System (Applied Biosystems, Foster City, Calif) in 20 μL reactions (10 μL 2x TaqMan Fast Advanced Master Mix \[Applied Biosystems\], 1 μL 20x primer and probe mixture for target gene, 1 μL 20x primer and probe mixture for β-glucuronidase (GUSB) plus cDNA equivalent to 10 ng of total RNA). Primer and probe sets were purchased from Applied Biosystems or Integrated DNA Technologies (Coralville, Iowa) and are shown in [Supplementary Table 3](#SD1){ref-type="supplementary-material"}. The mRNA expression levels were normalized to the percentage of expression of a housekeeping gene, GUSB.

Tissue homogenates and measurement of protein {#S12}
---------------------------------------------

Freshly obtained tissue specimens were prepared as previously described.^[@R5]^ The concentration of ECP, RANK-L, IL-5 and IL-13 in cell-free supernatants was measured by ELISA kit (MBL, Woburn, Mass), and Luminex multiplex assay (MILLIPLEX MAP Human RANK-L Magnetic Bead and MILLIPLEX MAP Human Cytokine/Chemokine Panel from EMD Millipore, Burlington, Mass). The minimal detection limits for ECP, RANK-L, IL-5 and IL-13 are 0.125 ng/ml, 5.0 pg/ml, 3.2 pg/ml and 3.2 pg/ml, respectively. The concentration of RANK-L, IL-13 and ECP in tissue homogenates was normalized to the concentration of total protein as detected by BCA protein assay kit (Thermo Fisher Scientific Inc., Waltham, Mass).

Cell isolation and cell sorting from human blood and NP tissue {#S13}
--------------------------------------------------------------

Human leukocytes were isolated from a human peripheral blood leuko pak (STEMCELL Technologies) by centrifugation at 500 g for 10 minutes with equal volume of dPBS with 2% fetal bovine serum (FBS) at room temperature. After aspiration of the supernatants, red blood cells were lysed by ammonium chloride solution (STEMCELL Technologies) and supernatants were removed after centrifugation at 300 g for 5 minutes. To remove platelets, cells were resuspended in dPBS + 2% FBS and centrifuged at 200 g for 10 minutes at room temperature. After removing the supernatants, ILC2s were enriched by EasySep™ Human ILC2 Enrichment Cocktail kit (STEMCELL Technologies) according to the manufacturer's instructions. After enrichment, cells were blocked by Fc Block reagent and then incubated with FITC anti-Lineage Cocktail (CD3, CD14, CD16, CD19, CD20, CD56), FITC anti-FcεRIa, FITC anti-CD11c, FITC anti-CD303, BUV395 anti-CD4, PE anti-CD5, Brilliant Violet 421 anti-CD45, Alexa Fluor 647 anti-CRTH2, PE/Cy7 anti-CD127 and APC/Cy7 anti-CD161. We then sorted blood ILC2s as CD45+, Lin (CD3, CD11c, CD14, CD16, CD19, CD20, CD56, CD303, FcεRIa)−, CD4−, CD5−, CD127+, CRTH2+, CD161+ cells with a BD FACSAria SORP cell sorter (BD Biosciences) at the Robert H Lurie Comprehensive Cancer Center at Northwestern University. All antibodies are listed in [Supplementary Table 4](#SD1){ref-type="supplementary-material"}.

We also sorted ILC2s, T~H~2 cells, CRTH2-CD4+ T cells and CXCL16+ cells from NPs from patients with CRSwNP. Tissue samples were fragmented and incubated with 30 μg/ml DNase I and 1 mg/ml type I collagenase containing media at 4°C overnight. Following this, tissues were minced using a gentleMACS dissociator (Miltenyi Biotec, Auburn, Calif) and the cells were filtered through 70 μm nylon mesh (BD Biosciences, San Jose, Calif). Cells were then treated with red blood cell lysis solution (Miltenyi Biotec) before counting and staining for cell sorting. After the isolation, cells were first treated with Aqua LIVE/DEAD fixable dead cell staining reagent (Invitrogen, Carlsbad, Calif) at room temperature in the dark. Cells were then blocked by Fc Block reagent and incubated with FITC anti-human Lineage Cocktail, FITC or PerCP/Cy5.5 anti-CD11c, FITC anti-CD303, PE-CXCL16, PE/Cy7 anti-FcεRIa or anti-HLA-DR, BUV395 anti-CD4, PE/Dazzle 594 anti-CD5, Alexa Fluor 700 anti-CD45, Alexa Fluor 647 anti-CRTH2, BV421 anti-CD127 and APC/Cy7 anti-CD161 at 4°C in the dark. We sorted ILC2s (Aqua−, CD45+, Lin (CD3, CD11c, CD14, CD16, CD19, CD20, CD56, CD303)−, CD4−, CD5−, FcεRIa−, CD127+, CRTH2+ and CD161+ cells) CRTH2− CD4+ T cells (Aqua−, CD45+, Lin+, FcεRIa−, CD5+, CD4+, CRTH2−), T~H~2 cells (Aqua−, CD45+, Lin+, FcεRIa−, CD5+, CD4+, CRTH2+) and CXCL16+ cells (Aqua−, CD45+, CD11c+, HLA-DR+ and CXCL16+ cells) with a BD FACSAria SORP cell sorter. The purity of blood and NP ILC2s was greater than 98% (not shown).

Cell culture {#S14}
------------

Sorted blood and NP ILC2s, T~H~2 cells, CRTH2-CD4+ cells and CXCL16+ cells (10,000 cells/ml) were suspended in RPMI 1640 medium supplemented with 25 IU/ml IL-2 (Prometheus, San Diego, Calif), 10% FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin as previously described.^[@R22]^ ILC2s were stimulated with 10 ng/ml TSLP (R&D systems, Minneapolis, Minn), 50 ng/ml RANK-L (R&D systems), 10 μg/ml goat control IgG (R&D systems) and 10 μg/ml agonistic anti-RANK antibody (R&D systems) in the presence or absence of 10 ng/ml IL-10 (R&D systems), 20 ng/ml TGF-β1 (R&D systems), 0.01% or 0.001% DMSO (Sigma-Aldrich, St. Louis, Mo), 100 nM dexamethasone (Sigma-Aldrich) and 10 nM IκB inhibitor IMD0354 (Selleckchem, Houston, Tex) for 4 days. We did dose-dependent experiments using 10--50 ng/ml RANK-L and 1--10 μg/ml anti-RANK antibody (n = 2, not shown) and then selected optimal concentrations for this study.

In the co-culture study, we performed a (1:1) co-culture using sorted ILC2s with CRTH2-CD4+ T cells, T~H~2 cells or CXCL16+ cells for 4 days. In some experiments, we performed co-culture of ILC2s with T~H~2 cells in the presence or absence of 10 μg/ml denosumab (Amgen inc., Thousand Oak, Calif) and 10 μg/ml isotype control human IgG2 (BioLegend, San Diego, Calif). In individual condition wells, we plated equal volumes of ILC2s (10,000 cells/ml), T cells (10,000 cells/ml) or CXCL16+ cells (10,000 cells/ml), and cytokine amounts were shown as pg from 10,000 ILC2s + 10,000 T cells or 10,000 DCs.

Flow cytometric analysis {#S15}
------------------------

Cells were first treated with Aqua dead cell staining reagent as a live/dead discriminator. Cells were then incubated with an Fc Block reagent (Miltenyi Biotec) for 10 minutes at 4°C in the dark. All antibodies are listed in [Supplementary Table 4](#SD1){ref-type="supplementary-material"}. Cells were stained for 30 minutes at 4°C in the dark and washed with MACS buffer (Miltenyi Biotech). After washing, cells were fixed with a BD Cytofix/Cytoperm Kit (BD Biosciences), resuspended in MACS buffer and stored at 4°C in the dark before analysis on a CytoFLEX flow cytometer (Beckman Coulter, Indianapolis, Ind). All analysis was performed with FlowJo software, version 10.1 (TreeStar, Ashland, Ore), and the experimental method was established and verified with the proper single-stained control beads (BD Biosciences and eBiosciences) and fluorescence minus one (FMO) negative controls (not shown).

Immunohistochemistry {#S16}
--------------------

Immunohistochemistry was performed as described previously.^[@R20],\ [@R50]^ For antigen retrieval, sections were placed in boiling 10 mM citrate buffer for 15 minutes and cooled slowly and rinsed. Sections were blocked for endogenous peroxidase activity with 3% hydrogen peroxide/methanol. After rinsing, tissue sections were blocked for nonspecific binding with 5% goat serum/0.3% Tween-20/PBS. After avidin/biotin blocking (Vector Laboratories, Burlingame, Calif), tissue sections were incubated with 0.25 μg/ml rabbit anti-human RANK-L polyclonal antibody (HPA045142, Sigma-Aldrich) or 0.25 μg/ml rabbit control IgG antibody (Thermo Fisher Scientific Inc.) overnight at 4°C. Sections were incubated in biotinylated secondary goat anti-rabbit IgG antibody (Vector Laboratories) at a 1:200 dilution for 1 hour at room temperature. After another rinse, sections were incubated in ABC reagent (avidin--biotin--horseradish peroxidase complex; Vector Laboratories) for 1 hour at room temperature. Sections were incubated with ImmPACT™ NovaRED™ reagent (Vector Laboratories) for 5 minutes at room temperature. Then they were rinsed in deionized H2O, counterstained with hematoxylin, dehydrated, cleaned, mounted, and coverslipped using Cytoseal 60 (Richard-Allan Scientific, Kalamazoo, Mich) in preparation for microscopic analysis. Slides were blinded, and 5 pictures were randomly taken from each slide using Olympus IX71 and cellSens Entry software (Olympus, Tokyo, Japan). The number of RANK-L positive cells in the nasal tissue was counted by 2 independent observers.

Statistics {#S17}
----------

All data were reported as the mean ± SEM. Normality tests were performed with Shapiro-Wilk normality test (2 groups) and Brown-Forsythe test (multiple groups). Comparisons of 2 groups were performed using Mann-Whitney test or Wilcoxon test if the data was non-parametric or using paired t-test or ratio paired t-test if the data was parametric. Multiple groups were compared using 1-way ANOVA Kruskal-Wallis test or Friedman test followed by a Dunns's post-test if the data was non-parametric or using 1-way ANOVA following by a Holm-Sidak's post-test if the data was parametric. A p value of less than 0.05 was considered significant. Correlations were assessed by Spearman correlation.
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BAFF

:   B cell activating factor of the TNF family

CLC

:   Charcot-Leyden Crystal

CRS

:   Chronic rhinosinusitis

CRSwNP

:   CRS with nasal polyps

DC

:   Dendritic cell

DR3

:   Death receptor 3

ECP

:   Eosinophil cationic protein

gMFI

:   Geometric mean fluorescence intensity

GUSB

:   β-glucuronidase

HLA-DR

:   Human leukocyte antigen-D related

ILC

:   Innate lymphoid cell

ILC1

:   Group 1 ILC

ILC2

:   Group 2 ILC

ILC3

:   Group 3 ILC

NF-κB

:   Nuclear factor-kappa B

NP

:   Nasal polyp

NSAID

:   Non-steroidal anti-inflammatory drug OPG, Osteoprotegerin

qPCR

:   Quantitative polymerase chain reaction

RANK

:   Receptor activator of NF-κB

RANK-L

:   RANK-ligand

RA

:   Rheumatoid arthritis

SSC

:   Side scatter

TGF-β

:   Transforming growth factor beta

TL1A

:   Tumor necrosis factor-like cytokine 1A

TNFSF

:   Tumor necrosis factor superfamily

TNFRSF

:   Tumor necrosis factor receptor superfamily

TSLP

:   Thymic stromal lymphopoietin

UT

:   Uncinate tissue

![Elevation of RANK-L in NPs and expression of RANK on human ILC2s. **a, e** Total RNA was extracted from whole control UT (Con, n = 21) and NP tissue (n = 39) from patients with CRSwNP. Expression of mRNAs for RANK-L and OPG was analyzed using qPCR. Gene expression was normalized to a housekeeping gene, β-glucuronidase (GUSB), and expression levels were shown as % expression of GUSB. **b** Representative histograms of flow cytometric plots for RANK on ILC2s in blood and NPs (n = 6) are shown. Levels of cell surface expression of RANK on ILC2s are shown by geometric mean fluorescence intensity (gMFI). **c** A comparison of the gMFI ratio of RANK to isotype IgG1 between blood ILC2s and NP ILC2s is shown. **d** Protein extracts were generated from control UT (Con, n = 13), NPs from CRSwNP patients who did not have NSAID sensitivity (n = 69) and who did have NSAID sensitivity (n = 12). Expression of RANK-L protein in tissue homogenates was determined by Luminex. RANK-L protein concentrations were normalized to the concentration of total protein.\*p \< 0.05, \*\*p \< 0.01 and \*\*\*p \< 0.001 were calculated by Mann-Whitney test (a, e), 1-way ANOVA Kruskal-Wallis test (d), paired-t test (b) and Wilcoxon test (c).](nihms-1541003-f0001){#F1}

![RANK-mediated production of type 2 cytokines in ILC2s. **a** Sorted blood ILC2s (n = 14) and **b** NP ILC2s (n = 8) were cultured in the presence or absence of 10 μg/ml agonistic anti-RANK antibody (a-RANK) for 4 days. **c-e** Sorted blood ILC2s were cultured with 10 ng/ml TSLP, 10 μg/ml a-RANK and their combination (c, n = 12) in the presence or absence of 0.001% dimethyl sulfoxide (DMSO) (vehicle control), 100 nM dexamethasone (Dex) (d, n = 7) and 10 μM IMD0354 (IMD) (e, n = 3) for 4 days. The concentrations of IL-5 and IL-13 were measured by Luminex assay. Not significant (NS), \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 and \*\*\*\*p \< 0.0001 were calculated by Wilcoxon test (a, b) and 1-way ANOVA Kruskal-Wallis test (c-e).](nihms-1541003-f0002){#F2}

![The main source of RANK-L was immune cells in NPs. The presence of RANK-L positive cells was assessed by immunohistochemistry. **a** Negative control antibody staining in NP is shown. **b, c** Representative immunostaining for RANK-L in NP (b) and control UT (c) are shown. **d** High magnification image of (b) is shown. **e** The number of RANK-L positive cells in control UT (n = 8) and NPs (n = 11) was counted. **f,** *left* Representative flow cytometric plots for RANK-L+ cells in NPs are shown. We gated on single, live, RANK-L positive (RANK-L+) cells compared to isotype control IgG2b. **f**, *right* RANK-L+ cells were further separated into CD45+ and CD45− populations and the frequency of RANK-L+ cells in the two populations was calculated (n = 12). \*p \< 0.05 and \*\*\*\*p \< 0.0001 were calculated by Mann-Whitney test (e) and pair-t test (f).](nihms-1541003-f0003){#F3}

![Identification of RANK-L expressing cells in NPs. **a** The frequency of granulocytes (Gran; SSC high and CD45+ cells), CD19+ B cells (CD45+CD19+CD3− cells), CD3+ T cells (CD45+CD3+ cells) and CD3-CD19− cells (SSC mid-low, CD45+CD3-CD19^mid-low^ cells) in RANK-L+CD45+ cells in NPs was calculated (n = 7). **b** The frequency of CD11c− cells, CD11c+ cells in RANK-L+CD45+ cells is shown (n = 7). **c** The frequency of mDC1 (CD1c^high^CD141-CD11c+ cells), mDC2 (CD141+CD1c-CD11c+ cells) and CD11c+ non-mDCs (CD1c^mid-low^CD141− cells) in RANK-L+CD45+ cells in NPs is shown (n = 3). **d, f** Representative histograms of flow cytometric plots and bar graphs for RANK-L on T~H~2 cells, CRTH2-CD4+ T cells (n = 9), CXCL16-HLADR+CD11c+ cells and CXCL16+HLA-DR+CD11c+ cells (n = 6), in NPs are shown. **e, g** Comparisons of the gMFI ratio of RANK-L to isotype IgG2b between T~H~2 cells and CRTH2CD4+ T cells and between CXCL16+ cells-, CXCL16− cells and ILC2s are shown. Not significant (NS), \*p \< 0.05, \*\*p \< 0.01 and \*\*\*\*p \< 0.0001 were calculated by 1-way ANOVA Kruskal-Wallis test (a, g), Holm-Sidak's multiple comparisons test (c), paired-t test (d, f) and Wilcoxon test (b, e).](nihms-1541003-f0004){#F4}

![The expression of CXCR6 and CCR4 on ILC2s and the elevation of CCL17 and CCL22 in NPs. **a, b** Representative histograms of flow cytometric plots and bar graphs for CXCR6 (a, n = 6) in NP ILC2s and CCR4 (b, n = 5) in NP ILC2s and NP T~H~2 cells are shown. Total RNA was extracted from whole control UT tissue (Con, n = 21) and whole NP tissue (n = 39). **c** Expression of mRNAs for CCL17 and CCL22 was analyzed using qPCR. \*p \< 0.05, \*\*p \< 0.01 and \*\*\*\*p \< 0.0001 were calculated by paired-t test (a, b) and Mann-Whitney test (c).](nihms-1541003-f0005){#F5}

![Co-culture of ILC2s with RANK-L expressing cells enhanced the production of type 2 cytokines. **a** The schema of our co-culture study is shown. **b, c, e** We performed a (1:1) cell number co-culture using sorted NP ILC2s with NP CRTH2-CD4+ T cells (n = 10, b), NP ILC2s with NP T~H~2 cells (n = 12, c) and NP ILC2s with NP CXCL16+ cells (n = 4, e) for 4 days. We also cultured equal numbers of NP ILC2s, NP CRTH2-CD4+ T cells, NP T~H~2 and NP CXCL16+ cells separately (Individual culture) for 4 days. **d, f** The ratio of IL-5 and IL-13 production in the co-culture of NP ILC2s with T~H~2 cells or ILC2s with CXCL16+ cells to the sum of individual culture is shown (d. n = 12, f. n = 4). **g** NP ILC2s were co-cultured with NP T~H~2 cells in the presence or absence of 10 μg/ml denosumab and isotype human control IgG2 (n = 8) for 4 days. The concentrations of IL-5 and IL-13 were measured by Luminex assay. Cytokine amounts were shown in pg from 10,000 ILC2s plus 10,000 T cells or 10,000 CXCL16+ cells. Not significant (NS), \*p \< 0.05, \*\*p \< 0.01 and \*\*\*p \< 0.001 were calculated by Wilcoxon test (b, c), ratio paired t-test (e) and Friedman test (g).](nihms-1541003-f0006){#F6}
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